• This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Sun - Fri 8:00 - 20:30
The 'Press Releases' section offers the latest product-specific and company-related updates to our esteemed clients, providing them with a valuable resource. Members can leverage this platform for quick, efficient, and effective visibility.

— Our press release programs complement our content distribution initiatives, ensuring strong positioning across major media outlets and social media channels. This enhances the visibility of your message within the global pharmaceutical industry.
Louis Denis, M.D., Chief Medical Officer, Byondis

Byondis Appoints Louis Denis, M.D., as Chief Medical Officer

Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces the appointment of Louis Denis, M.D. as Chief Medical Officer. Dr. Denis brings more than 30 years of clinical development leadership and oncology expertise to Byondis.

Read more →
Nevro's revolutionary transfixing implant technology

A new study highlights the Nevro1™ SI Joint Fusion System's advantages over traditional posterolateral and lateral approaches, showcasing its innovative design and clinical benefits

Nevro Corp. a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,announced the publication of new data in Medical Devices: Evidence and Research, which demonstrate the superiority of the Nevro1™ SI Joint Fusion System ("Nevro1").

Read more →
WATCHMAN FLX™ Left Atrial Appendage Closure Device

Boston Scientific's WATCHMAN FLX™ device shows superior bleeding risk reduction compared to oral anticoagulants after cardiac ablation, according to the OPTION trial

Boston Scientific Corporation announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Key findings from the study comparing the device to first-line oral anticoagulation (OAC) – including direct oral anticoagulants (DOAC) (95%) and warfarin (5%) – for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablation were presented in a late-breaking science session at the American Heart Association's Scientific Sessions 2024, and simultaneously published in The New England Journal of Medicine.

Read more →
prodisc L for 2-Level Use.

Centinel Spine's prodisc® L Total Disc Replacement gains expanded coverage from top Mid-Atlantic insurers, advancing access to one- and two-level lumbar procedures

Centinel Spine®, LLC  the leading global medical device company focused exclusively on treating cervical and lumbar spinal disease with the most complete and clinically-proven total disc replacement (TDR) technology platform in the world (prodisc®),  announced significant expansion of coverage for lumbar TDR procedures in the Mid-Atlantic region of the U.S.

Read more →
Avantor

Avantor® Unveils Bridgewater Innovation Center New facility dedicated to tackling critical life science challenges

Avantor, Inc. a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries,announced the opening of its new flagship Bridgewater Innovation Center. The state-of-the-art research and development facility, located in Bridgewater, NJ, is part of Avantor's network of 13 research and innovation centers across the globe.

Read more →
Bracco Group

Bracco Diagnostics Inc. reaches one million injections milestone with its MRI agent, VUEWAY® (gadopiclenol)

Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, is proud to announce that its most recently FDA-approved magnetic resonance imaging (MRI) agent, VUEWAY® (gadopiclenol) solution for injection, has reached over one million patient injections at over 480 customer sites.

Read more →
Quattrii Dry Powder Inhaler (DPI)

Aptar Pharma partners with Cambridge Healthcare Innovations to bring the Quattrii Dry Powder Inhaler to market

Aptar Pharma, a global leader in drug delivery and active material science solutions and services, announced that it has entered into an exclusive collaboration agreement with Cambridge Healthcare Innovations (CHI) to lead the commercialization and promotion of its Quattrii Dry Powder Inhaler (DPI) platform.

Read more →